|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1981
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:atccode
|
N02 AE01
|
|
gptkbp:bioavailability
|
30-40%
|
|
gptkbp:brand
|
gptkb:Suboxone
gptkb:Subutex
|
|
gptkbp:can_be_combined_with
|
gptkb:naloxone
|
|
gptkbp:casnumber
|
52485-79-1
|
|
gptkbp:chemical_formula
|
C29 H41 NO4 S
|
|
gptkbp:class
|
benzomorphan
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
acute or severe asthma
hypersensitivity to buprenorphine
severe respiratory insufficiency
|
|
gptkbp:dependency
|
yes
|
|
gptkbp:developed_by
|
gptkb:Reckitt_Benckiser
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:patches
gptkb:film
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Buprenorphine
|
|
gptkbp:indication
|
moderate to severe pain
opioid dependence
|
|
gptkbp:interacts_with
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:is_monitored_by
|
respiratory rate
liver function
pain level
|
|
gptkbp:legal_status
|
controlled substance
|
|
gptkbp:lifespan
|
24-60 hours
|
|
gptkbp:marketed_as
|
gptkb:Suboxone_film
Subutex tablet
|
|
gptkbp:mechanism_of_action
|
partial agonist at mu-opioid receptors
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_products
|
gptkb:health_services
morphine
methadone
|
|
gptkbp:research_areas
|
substance use disorder
pain management
|
|
gptkbp:route_of_administration
|
sublingual
transdermal
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
allergic reaction
withdrawal symptoms
constipation
sedation
respiratory depression
|
|
gptkbp:synthesis_year
|
gptkb:1969
|
|
gptkbp:tolerance_potential
|
yes
|
|
gptkbp:used_for
|
pain management
opioid addiction treatment
|
|
gptkbp:bfsParent
|
gptkb:Sub-Lingual_Tablet
|
|
gptkbp:bfsLayer
|
5
|